Congress Wealth Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Congress Wealth Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-177,801	Closed	-$6.06M	–	739
2024 Q1	$6.06M	Buy	177,801 +48,750	+38%	+$1.45M	0.1%	207
2023 Q4	$3.73M	Sell	129,051 -30,095	-19%	-$798K	0.07%	251
2023 Q3	$4.39M	Buy	159,146 +6,502	+4%	+$198K	0.09%	228
2023 Q2	$4.59M	Buy	152,644 +1,206	+0.8%	+$42.2K	0.11%	199
2023 Q1	$5.49M	Buy	151,438 +17,486	+13%	+$672K	0.13%	178
2022 Q4	$4.78M	Sell	133,952 -3,644	-3%	-$127K	0.12%	184
2022 Q3	$4.66M	Sell	137,596 -1,138	-0.8%	-$37K	0.13%	186
2022 Q2	$4.01M	Sell	138,734 -4,111	-3%	-$118K	0.1%	209
2022 Q1	$4.62M	Buy	142,845 +28,999	+25%	+$889K	0.1%	215
2021 Q4	$3.32M	Buy	+113,846	New	+$3.45M	0.07%	267

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Congress Wealth Management's SUPN Position: Q2 2024 in Review

Congress Wealth Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2024, closing a stake of 177,801 shares — an estimated $6.06M sold.

Congress Wealth Management first reported a position in SUPN in Q4 2021 and held it in 10 quarters. The position peaked at $6.06M in Q1 2024. 244 funds tracked by Wall St. Rank hold SUPN as of Q2 2024.

Congress Wealth Management reported no remaining Supernus Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Congress Wealth Management sold 177,801 Supernus Pharmaceuticals shares in Q2 2024, an estimated $6.06M.
Congress Wealth Management first reported a position in Supernus Pharmaceuticals in Q4 2021 and held it in 10 quarters.
Congress Wealth Management's Supernus Pharmaceuticals position peaked at $6.06M in Q1 2024.
244 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2024.

Based on Congress Wealth Management's 13F filing for Q2 2024, filed 14 Aug 2024.